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, (T2DM).1 These medications effectively regulate
glucose metabolism and have favorable effects on the
myocardium and vascular system.2 GLP-1RAs may also
have additional cardioprotective effects such as weight
loss.3 Evidence from randomized clinical trials supports
the cardiovascular safety of GLP-1RAs4 and recent clinical
trial data with GLP-1RAs have shown an improvement
in major adverse cardiac events (MACE) including
cardiovascular death, non-fatal myocardial infarction
(MI) and non-fatal stroke.5,6 However, a prior GLP-1RA
trial was neutral with respect to MACE4 suggesting the
lack of a class effect and highlighting the need for empiric
evaluation of different agents in this class.
TheEXSCEL trial is an academically led, placebo-controlled
randomized trial of the GLP-1RA exenatide-once-weekly
(EQW) in patients with T2DM7 that has recently completed
enrollment. This is a pragmatic trial8 designed to assess the
intervention in a real-world setting with broad entry criteria
and streamlined trial conduct (eg, study visits every 6
months, laboratory evaluations as part of routine care) to
enhance generalizability. The primary objective of EXSCEL is
to evaluate the effect of EQW, used in addition to the current 
usual care for glycemic control and other CV risk factors, on 
major macrovascular events when administered to patients 
with T2DM. The study includes both a primary safety 
hypothesis, that EQW is non-inferior to usual care for MACE, 
and a primary efficacy hypothesis, that EQW is superior to 
usual care for MACE.
EXSCEL is unique in that it enrolled patients with a 
broad range of cardiovascular risk (including those 
without a prior cardiovascular event) and was not 
enriched for older people or other specific cardiovascular 
risk factors, allowed dual usage of incretin therapies 
[GLP-1 agonist investigational product and dipeptidyl 
peptidase-4 (DPP-4) inhibitor use] and did not include a 
run-in period often included to select more compliant 
patients than in routine practice. Additionally, there are 
both primary safety and efficacy hypotheses in EXSCEL in 
contrast to many other large T2DM cardiovascular 
outcomes trials with only a primary hypothesis of 
non-inferiority.4,5 In the present manuscript, we describe 
the baseline characteristics of EXSCEL participants 
according to their baseline prior cardiovascular event 
status and enrolling region and compare patients with 
those enrolled in prior large GLP-1RA trials.
Methods
The EXSCEL trial is an ongoing, multinational, double-
blind, placebo-controlled, randomized trial of the once-
weekly GLP-1RA exenatide (EQW) at a dose of 2 mg in 
addition to usual care for T2DM. The study background 
and design has been previously published.7 In brief, the 
trial enrolled participants with a broad range of 
cardiovascular risk, from 688 sites in 35 countries from 
North America, Latin America, Europe, and Asia Pacific. 
Randomization targeted approximately 70% with a 
history of a cardiovascular event and 30% without 
known cardiovascular disease as detailed in the design 
manuscript.7 In brief, a prior cardiovascular event was 
defined as at least one of the following: a major clinical 
manifestation of coronary artery disease (CAD), ischemic 
cerebrovascular disease or atherosclerotic peripheral arterial 
disease (PAD). The trial has completed recruitment and is 
currently in the follow-up phase until the target event number 
of 1360 subjects with a confirmed primary composite 
outcome, defined as cardiovascular death, nonfatal myocar-
dial infarction, or nonfatal stroke, has accrued.
In the present manuscript, baseline characteristics are 
presented in a blinded manner for the entire trial 
population according to prior cardiovascular event status 
at enrollment and by region. Regions were defined a 
priori (see Supplemental Table I for countries within each 
region) and broadly conform to regions defined in other 
studies in this field to facilitate comparison. We also 
compare EXSCEL patients with those enrolled in prior 
large GLP-1RA trials.4-6No extramural funding was used to support this work.
The authors are solely responsible for the design and
conduct of this study, all study analyses, the drafting and
editing of the manuscript, and its final contents.
Results
Overall, 14,752 participants were randomized between
June 2010 and September 2015. The baseline character-
istics of the full population are presented in Table I. The
majority of patients enrolled in EXSCEL were white
(75.8%) with inclusion of 9.8% Asian and 6.0% Black.
With regard to ethnicity, 3028 patients (20.5%) reported
being Hispanic or Latino. The median (IQR) age was 63
years (56, 69), 38% were female, and 16% had a prior
history of heart failure (HF). The median (IQR) HbA1c,
diabetes duration, and body mass index (BMI) were 8.0%
(7.3, 8.9), 12 (7, 18) years, and 32 (28, 36) kg/m2,
respectively. The most common anti-diabetic medication
was metformin (76.5%) followed by insulin (46.2%) and
sulfonylureas (36.6%), and DPP-4 inhibitors (14.9%). The
baseline use of thiazolidinediones and SGLT-2 Inhibitors
was low at 3.9% and 0.9%, respectively.
In terms of World region, 6,788 (46.0%) patients were
enrolled in Europe; 3,708 (25.1%), North America; 2,727
(18.5%), Latin America; and 1529 (10.4%), Asia Pacific.
Figure 1 shows the enrollment by regions in EXSCEL.
Supplemental Table I presents the number of sites and
patients enrolled in each country. Table I presents
baseline characteristics by World region. Patients from
North America tended to be older with a longer duration
of DM, a higher BMI and more CAD compared to other
regions. Nearly half of the patients from Latin America
were women and PAD was more prevalent in Latin
America than other regions, yet statin and anti-platelet use
was the lowest. Patients from Asia Pacific had the lowest
BMI and had less usage of angiotensin converting enzyme
(ACE)-inhibitors and angiotensin receptor blockers
(ARBs) compared to other regions. In Europe, patients
had the highest baseline blood pressure and nearly a
quarter of patients had a prior history of HF.
With regard to baseline cardiovascular disease, 73% had
at least one prior cardiovascular event (70% CAD, 24%
PAD, 22% cerebrovascular disease). Table II presents
characteristics by baseline cardiovascular event status.
The patients with a prior cardiovascular event tended to
be older men with a longer duration of T2DM and worse
renal function, but lower BMI and low-density lipoprotein
(LDL) cholesterol, and similar blood pressure and HbA1c
compared to those without known prior cardiovascular
events at baseline. Compared to patients without a prior
cardiovascular event, patients with a prior cardiovascular
event had similar usage of DPP-4 inhibitors, less
metformin and sulfonylurea use, and more insulin
therapy. Evidence-based medications to address cardio-
vascular risk (eg, anti-hypertensive therapy, aspirin,











Age (y) 62.7 (56.4, 68.8) 64.1 (57.4, 70.3) 61.5 (55.0, 68.0) 61.4 (55.1, 67.4) 62.7 (56.8, 68.6)
Min/max 21.1, 92.6 23.6, 89.9 24.4, 92.6 25.7, 87.9 21.1, 88.7
b40 y 205 (1.4%) 56 (1.5%) 55 (2.0%) 30 (2.0%) 64 (0.9%)
40 to b65 y 8606 (58.3%) 1912 (51.6%) 1689 (61.9%) 954 (62.4%) 4051 (59.7%)
65 to 75 y 4690 (31.8%) 1294 (34.9%) 777 (28.5%) 455 (29.8%) 2164 (31.9%)
N75 y 1251 (8.5%) 446 (12.0%) 206 (7.6%) 90 (5.9%) 509 (7.5%)
Women 5604 (38.0%) 1142 (30.8%) 1341 (49.2%) 574 (37.5%) 2547 (37.5%)
Race
White 11,175 (75.8%) 2800 (75.6%) 1494 (54.8%) 300 (19.6%) 6581 (97.0%)
Asian 1452 (9.8%) 120 (3.2%) 7 (0.3%) 1212 (79.3%) 113 (1.7%)
Hispanic 1134 (7.7%) 329 (8.9%) 799 (29.3%) 0 (0.0%) 6 (0.1%)
Black 878 (6.0%) 430 (11.6%) 374 (13.8%) 1 (0.1%) 73 (1.1%)
Indian or Alaska Native 73 (0.5%) 12 (0.3%) 51 (1.9%) 0 (0.0%) 10 (0.1%)
Pacific Islander or Hawaiian 35 (0.2%) 14 (0.4%) 1 (0.0%) 16 (1.0%) 4 (0.1%)
Ethnicity
Hispanic or Latino 3026 (20.5%) 366 (9.9%) 2564 (94.0%) 7 (0.5%) 89 (1.3%)
Non-Hispanic or Latino 11,724 (79.5%) 3340 (90.1%) 163 (6.0%) 1522 (99.5%) 6699 (98.7%)
Diabetes duration (y) 12 (7, 18) 13 (7, 19) 11 (6, 18) 11 (7, 18) 11 (7, 17)
b5 y 2018 (13.7%) 489 (13.2%) 454 (16.7%) 207 (13.6%) 868 (12.8%)
≥5 to b15 y 7264 (49.4%) 1693 (45.9%) 1248 (45.8%) 761 (50.0%) 3562 (52.7%)
≥15 y 5420 (36.9%) 1510 (40.9%) 1022 (37.5%) 554 (36.4%) 2334 (34.5%)
History of cardiovascular disease
Coronary artery disease 7501 (69.6%) 2307 (86.7%) 1083 (52.1%) 811 (70.8%) 3300 (67.4%)
Cerebrovascular disease 2419 (22.4%) 538 (20.2%) 267 (12.8%) 302 (26.4%) 1312 (26.8%)
Peripheral artery disease 2540 (23.6%) 368 (13.8%) 918 (44.1%) 151 (13.2%) 1103 (22.5%)
History of retinopathy 2511 (17.0%) 465 (12.5%) 347 (12.7%) 242 (15.8%) 1457 (21.5%)
History of heart failure 2385 (16.2%) 403 (10.9%) 241 (8.8%) 77 (5.0%) 1664 (24.5%)
NYHA class
I 736 (30.9%) 143 (35.6%) 106 (44.0%) 44 (57.1%) 443 (26.7%)
II 1333 (55.9%) 204 (50.7%) 114 (47.3%) 28 (36.4%) 987 (59.4%)
III 301 (12.6%) 51 (12.4%) 19 (7.9%) 5 (6.5%) 226 (13.6%)
IV 13 (0.5%) 5 (1.2%) 2 (0.8%) 0 (0.0%) 6 (0.4%)
Most recent assessment of LV function (ejection fraction)
Normal (N55%) 2924 (59.8%) 911 (60.2%) 331 (62.5%) 273 (66.1%) 1409 (57.9%)
Mild dysfunction (40-55%) 1497 (30.7%) 432 (28.5%) 135 (25.5%) 95 (23.0%) 835 (34.3%)
Moderate dysfunction (25-39%) 388 (7.9%) 134 (8.9%) 49 (9.2%) 36 (8.7%) 169 (7.0%)
Severe dysfunction (b25%) 81 (1.7%) 37 (2.4%) 15 (2.8%) 9 (2.2%) 20 (0.8%)
Systolic blood pressure (mmHg) 135 (124, 145) 130 (120, 140) 135 (122, 149) 131 (121, 144) 138 (129, 147)
Diastolic blood pressure (mmHg) 80 (70-85) 75 (68-81) 80 (71-86) 79 (70-84) 80 (73-86)
Heart rate (bpm) 72 (66, 80) 72 (64, 79) 72 (65, 80) 74 (68, 81) 72 (67, 80)
Body mass index (kg/m2) 31.8 (28.2, 36.2) 33.6 (29.7, 38.3) 29.8 (26.8, 33.3) 27.3 (24.5, 31.2) 32.7 (29.4, 36.9)
b30 kg/m2 5355 (36.7%) 976 (26.8%) 1388 (51.1%) 1036 (69.0%) 1955 (29.0%)
≥30 kg/m2 9247 (63.3%) 2668 (73.2%) 1328 (48.9%) 465 (31.0%) 4786 (71.0%)
HbA1c (%) 8.0 (7.3, 8.9) 7.9 (7.3, 8.7) 8.1 (7.4, 9.1) 8.0 (7.4, 8.9) 8.0 (7.3, 8.9)
Min/max 5.6, 12.7 5.6, 12.7 5.9, 10.9 6.1, 12.6 6.0, 11.7
Mean (SD) in patients b8% 7.3 (0.4) 7.3 (0.4) 7.3 (0.4) 7.3 (0.4) 7.3 (0.4)
Mean (SD) in patients ≥8% 8.9 (0.6) 8.9 (0.6) 9.0 (0.6) 8.9 (0.7) 8.9 (0.6)
LDL (mg/dL) 88 (66, 116) 76 (60, 98) 100 (74, 128) 84 (65, 110) 93 (71, 124)
eGFR via MDRD (mL/min per 1.73 m2) 79 (64, 96) 78 (62, 95) 78 (64, 93) 81 (64, 99) 81 (66, 96)
N90 5036 (34.2%) 1214 (32.7%) 854 (31.3%) 567 (37.1%) 2401 (35.4%)
60-89 6953 (47.2%) 1684 (45.4%) 1342 (49.2%) 687 (45.0%) 3240 (47.8%)
30-59 2743 (18.6%) 807 (21.8%) 527 (19.3%) 270 (17.7%) 1139 (16.8%)
Anti-DM therapies
Metformin 11,289 (76.5%) 2617 (70.6%) 2250 (82.5%) 1164 (76.1%) 5258 (77.5%)
Sulfonylurea 5402 (36.6%) 1416 (38.2%) 1144 (42.0%) 659 (43.1%) 2183 (32.2%)
Thiazolidinedione 579 (3.9%) 342 (9.2%) 21 (0.8%) 74 (4.8%) 142 (2.1%)
DPP-4 inhibitor 2202 (14.9%) 641 (17.3%) 211 (7.7%) 240 (15.7%) 1110 (16.4%)
SGLT-2 inhibitor 77 (0.9%) 15 (0.9%) 10 (0.5%) 3 (0.3%) 49 (1.3%)












Insulin 6819 (46.2%) 1591 (42.9%) 1215 (44.6%) 698 (45.7%) 3315 (48.8%)
And 0-2 oral AHAs 6738 (45.7%) 1575 (42.5%) 1202 (44.1%) 689 (45.1%) 3272 (48.2%)
And N2 oral AHAs 81 (0.5%) 16 (0.4%) 13 (0.5%) 9 (0.6%) 43 (0.6%)
Monotherapy (including oral agents and insulin) 2687 (32.0%) 572 (33.7%) 640 (32.0%) 236 (25.0%) 1239 (33.0%)
2 oral therapies 1914 (46.8%) 338 (46.3%) 569 (53.7%) 195 (47.2%) 812 (43.1%)
No glucose lowering therapy 125 (1.5%) 35 (2.1%) 24 (1.2%) 18 (1.9%) 48 (1.3%)
Cardiovascular medications
Aspirin 9372 (63.5%) 2685 (72.5%) 1594 (58.5%) 920 (60.2%) 4173 (61.5%)
Thienopyridines 2521 (17.1%) 730 (19.7%) 333 (12.2%) 322 (21.1%) 1136 (16.7%)
Any anti-platelets 10,310 (69.9%) 2871 (77.5%) 1659 (60.8%) 1089 (71.2%) 4691 (69.1%)
ACEI or ARB 11,386 (77.2%) 2881 (77.7%) 1938 (71.1%) 1029 (67.3%) 5538 (81.6%)
β-Blockers 8208 (55.6%) 2166 (58.4%) 1085 (39.8%) 714 (46.7%) 4243 (62.5%)
Calcium-channel blocker 4701 (31.9%) 1024 (27.6%) 609 (22.3%) 592 (38.7%) 2476 (36.5%)
Any anti-hypertensive 13,318 (90.3%) 3424 (92.4%) 2220 (81.4%) 1320 (86.3%) 6354 (93.6%)
Statin 10,836 (73.5%) 3094 (83.5%) 1617 (59.3%) 1143 (74.8%) 4982 (73.4%)
Any lipid-lowering Rx 11,364 (77.0%) 3210 (86.6%) 1746 (64.0%) 1197 (78.3%) 5211 (76.8%)
AHA, Anti-hyperglycemic agents; HbA1c, hemoglobin A1c; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease;
DPP-IV, dipeptidyl peptidase; SGLT-2, sodium-glucose co-transporter 2; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
Figure 1
Enrollment of EXSCEL trial participants by World Region.
l I ( ti )statin) were used more frequently in the secondary
prevention population.Nonetheless, the primary prevention
population demonstrated 81% use of an anti-hypertensive,
57% statin use and 38% aspirin use at baseline.Table III presents the EXSCEL design and baseline character-
istics compared to prior cardiovascular outcomes studies with
GLP-1RAs.Notabledifferences include the lackofanagecriterion
in EXSCEL and a primary efficacy hypothesis of superiority.
Table II. Baseline characteristics by baseline CV status




Age (years) 59.4 (52.5, 65.7) 63.9 (57.9, 69.7)
Min/max 21.1, 92.6 25.7, 90.2
b40 y 150 (3.8%) 54 (0.5%)
40 to b65 y 2730 (68.8%) 5875 (54.5%)
65 to 75 y 902 (22.7%) 3788 (35.1%)
N75 y 187 (4.7%) 1064 (9.9%)
Women 2023 (51.0%) 3580 (33.2%)
Race
White 3040 (76.6%) 8133 (75.5%)
Asian 327 (8.2%) 1125 (10.4%)
Hispanic 331 (8.3%) 803 (7.5%)
Black 251 (6.3%) 627 (5.8%)
Indian or Alaska Native 10 (0.3%) 63 (0.6%)
Pacific Islander or Hawaiian 9 (0.2%) 26 (0.2%)
Ethnicity
Hispanic or Latino 755 (19.0%) 2271 (21.1%)
Non-Hispanic or Latino 3214 (81.0%) 8508 (78.9%)
DM duration (y) 10 (6, 15) 12 (7, 19)
b5 y 703 (17.7%) 1315 (12.2%)
≥5 to b15 y 2180 (55.0%) 5083 (47.3%)
≥15 y 1078 (27.2%) 4341 (40.4%)
History of retinopathy 467 (11.8%) 2044 (19.0%)
History of heart failure 321 (8.1%) 2064 (19.1%)
NYHA class
I 119 (37.1%) 617 (29.9%)
II 172 (53.6%) 1161 (56.3%)
III 30 (9.3%) 271 (13.1%)
IV 0 (0.0%) 13 (0.6%)
Most recent assessment of LV function (ejection fraction)
Normal (N55%) 477 (77.2%) 2447 (57.3%)
Mild dysfunction (40-55%) 118 (19.1%) 1379 (32.3%)
Moderate dysfunction (25-39%) 18 (2.9%) 370 (8.7%)
Severe dysfunction (b25%) 5 (0.8%) 76 (1.8%)
Systolic BP (mmHg) 134 (124, 144) 135 (124, 146)
Diastolic BP (mmHg) 80 (74-86) 79 (70-84)
Heart rate (bpm) 75 (68, 81) 72 (64, 79)
BMI (kg/m2) 33.0 (29.1, 37.9) 31.4 (28.0, 35.6)
b30 kg/m2 1213 (30.9%) 4142 (38.8%)
≥30 kg/m2 2715 (69.1%) 6531 (61.2%)
HbA1c (%) 8.0 (7.4, 8.9) 8.0 (7.3, 8.9)
LDL (mg/dL) 99 (75, 126) 84 (64, 112)
eGFR via MDRD (mL/min per 1.73m2) 85 (71, 103) 77 (62, 93)
N90 1718 (43.3%) 3317 (30.8%)
60-89 1774 (44.7%) 5179 (48.1%)
30-59 473 (11.9%) 2269 (21.1%)
Anti-DM therapies
Metformin 3375 (85.1%) 7914 (73.4%)
Sulfonylurea 1708 (43.0%) 3694 (34.3%)
Thiazolidinedione 278 (7.0%) 301 (2.8%)
DPP-4 Inhibitor 692 (17.4%) 1510 (14.0%)
SGLT-2 Inhibitor 24 (1.4%) 53 (0.8%)
Insulin 1257 (31.7%) 5562 (51.6%)
And 0-2 oral AHAs 1240 (31.2%) 5498 (51.0%)
And N2 oral AHAs 17 (0.4%) 64 (0.6%)
Monotherapy (including oral agents and insulin) 444 (26.9%) 2243 (33.2%)
No glucose lowering therapy 37 (2.2%) 88 (1.3%)
Cardiovascular medications
Aspirin 1525 (38.4%) 7847 (72.8%)
Thienopyridines 64 (1.6%) 2457 (22.8%)
Any anti-platelets 1600 (40.3%) 8710 (80.8%)
ACEI or ARB 2765 (69.7%) 8621 (80.0%)
(continued on next page)
Table II (continued)




β-Blockers 1263 (31.8%) 6945 (64.4%)
Calcium channel blocker 1060 (26.7%) 3641 (33.8%)
Any anti-hypertensive 3197 (80.5%) 10,121 (93.9%)
Statin 2260 (56.9%) 8576 (79.5%)
Any lipid-lowering Rx 2473 (62.3%) 8891 (82.5%)
l II ( ti )Discussion
The EXSCEL trial enrolled more than 14,000 patients
worldwide in order to assess the safety and efficacy of the
GLP-1RA EQW. Nearly half of the patients were enrolled
in Europe with significant contributions from North
America (25%), Latin America (19%), and Asia Pacific
(10%). After completion of enrollment, there were
notable differences between regions with respect to
baseline characteristics and pharmacotherapy for both
DM and cardiovascular disease. EXSCEL is one of the first
large-scale outcome trials with a GLP-1RA to allow
co-therapy with DPP-4 inhibitors and approximately
15% of patients received these agents at baseline. EXSCEL
was also unique in the inclusion of patients with a broad
range of cardiovascular risk including approximately 30%
without known cardiovascular disease and nearly 50% on
insulin at baseline.
EXSCEL has several distinct features related to the
enrolled patient population compared to previous
GLP-1RA outcomes trials (Table III). The ELIXA trial
(Evaluation of LIXisenatide in Acute Coronary Syndrome)
investigated the GLP-1RA lixisenatide compared with
placebo in 6068 patients with an acute coronary
syndrome (myocardial infarction in 83% and unstable
angina in 17%) within the previous 180 days9. Thus, only
secondary prevention patients were included in the trial.
Patients in ELIXA were younger (60 vs 63 years) with
lower BMI (30 vs 32 kg/m2) and shorter duration of
diabetes (9 years vs 12 years) compared with patients in
EXSCEL. ELIXA also incorporated a run-in period prior to
randomization which selected for the more compliant
patients, and thus may limit broader generalizability.
ELIXA met its primary endpoint of non-inferiority for
MACE-4 but not superiority over a median follow-up of
2.1 years.
The LEADER trial investigated liraglutide compared
with placebo in 9340 diabetics at high risk for cardiovas-
cular events.10 Patients were required to be ≥50 years at
screening in contrast to EXSCEL which did not have an
age criterion beyond adulthood (18 years). Overall, 81%
of LEADER patients were identified as having prior
cardiovascular disease and 19% were without prior
cardiovascular disease compared to 27% without a prior
cardiovascular event in EXSCEL. However, the definitionof prior cardiovascular disease in LEADER also included
those with renal impairment or chronic HF in comparison
to the requirement in EXSCEL for at least one of the
following: CAD, PAD or ischemic cerebrovascular
disease. Moreover, the LEADER trial enriched the primary
prevention cohort through additional requirements (e.g.,
≥60 years and concomitant disease history of either
documented nephropathy, underlying cardiac abnormal-
ities [left ventricular hypertrophy or ventricular dysfunc-
tion] or evidence of PAD). Similar to ELIXA, LEADER also
incorporated a run-in period prior to randomization. This
design characteristic as well as the risk factor enrichment
for the subgroup without prior cardiovascular disease
may limit generalization to the broader population of
patients with type 2 diabetes.
Patients in LEADER had a similar mean age (64 years)
and BMI (32.5 kg/m2) compared to the EXSCEL cohort
but the baseline HbA1c was higher in LEADER (8.7% vs
8.0%). LEADER met its primary endpoint of non-inferior-
ity for MACE-3 and also demonstrated superiority (HR
0.87, 95% CI: 0.78-97, P = .01 for superiority) over a
median follow-up of 3.8 years. Therefore, LEADER was
the first GLP-1 agonist outcome study to demonstrate
superiority for cardiovascular outcomes.
The SUSTAIN-6 trial investigated the GLP-1RA semaglu-
tide in 3297 patients with T2DM.6 Eligible patients were
≥50 years old with clinical evidence of cardiovascular
disease or ≥60 years old with subclinical cardiovascular
disease. The SUSTAIN-6 patient population had the oldest
age of the GLP-1RA outcomes trials completed to date and
had the longest duration of DM as well as the highest usage
of insulin at baseline. With a 104-week treatment period,
the trial met its primary endpoint of non-inferiority for
MACE (HR 0.74; 95% CI: 0.58-0.95, P b .001) as well as a
statistical significant reduction in CV risk with 254 primary
MACE events. Therewas a significant reduction in non-fatal
stroke, a numerical reduction in non-fatal MI and a neutral
relationship with CV death. Thus, SUSTAIN-6 included an
age entry criterion and targeted patients with known CV or
kidney disease or CV risk factorswith amodest event count
over an observation period of approximately 2 years.
Importantly, certain effects of the GLP-1RAs appear to
represent class effects while there are also unique aspects
of their efficacy and safety that may differ within this class
Table III. Prior global cardiovascular outcomes trials for incretin-based therapies compared with EXSCEL
Design and baseline
characteristics ELIXA LEADER SUSTAIN-6 EXSCEL
Treatment Lixisenatide Liraglutide Semaglutide Exenatide
No. of patients 6068 9340 3297 14,752
No. of primary events 805 1302 254 Targeting 1360
Key entry criteria A1c 5.5-11%













as well as primary
prevention
(27% enrolled)
Age criterion ≥30 y ≥50 years with
CV disease,
renal dysfunction
or HF or ≥60 years




CVD or ≥60 years
with subclinical CVD
No specific age criterion
Duration of
follow up (median)
2.1 y 3.8 y 2.1 y Pending













P b .01 for NI
P = NS for superiority
HR 0.87 (0.78-0.97)
P b .001 for NI
P = .01 for superiority
HR 0.74 (0.58-0.95)
P b .001 for NI
Pending
Age (y) 60 64 65 63
Men 70% 64% 61% 62%
DM duration (y) 9.3 13 14 12
BMI (kg/m2) 30 33 33 32
White 75% 78% 83% 76%
Asian 12% 10% 8% 10%
GFR (mL/min per 1.73 m2) 75 NR NR 79
Insulin 39% 42% 58% 46%
Metformin 66% 76% 73% 77%
SU 33% 51% 43% 37%
TZD 2% 6% 2% 4%
Aspirin 97% antiplatelet 63% 64% 64%
Statin 93% 72% 73% 74%
ACE-I/ARB 85% 51%/32% 50%/34% 77%
DM, Diabetes mellitus; BMI, body mass index; GFR, glomerular filtration rate; SU, sulfonylurea; TZD, thiazolidinedione; ACE-ARB, angiotensin converting enzyme inhibitor,
angiotensin receptor blocker; GLP-1, glucagon-like peptide-1; DPP-4, dipeptidyl peptidase-4.
MACE-3, CV-related death, non-fatal MI, or non-fatal stroke.
MACE-4, CV-related death, non-fatal MI, non-fatal stroke, or UA requiring hospitalization.as reviewed previously.11 Overall, GLP-1RAs improve
glycemic control while reducing body weight and
systolic blood pressure. Moreover, due to their glucose--
dependent mechanism, the incidence of hypoglycemia is
relatively low with these treatments compared to other
anti-hyperglycemic therapies. In terms of duration of
action, there are currently short-acting formulations that
are administered once or twice daily (eg, exenatide,
liraglutide and lixisenatide) compared with long-acting
formulations that are injected weekly (eg, exenatide,
albiglutide, dulaglutide). Long-acting agents may produce
superior glucose lowering with less nausea than the
shorter acting therapies. Comparative effectiveness data
with regard to clinical outcomes and safety are needed
within this medication class.Differences in baseline characteristics were observed
across enrolling regions in EXSCEL. One notable interna-
tional variation was the baseline prevalence of HF. The
overall trial prevalence was 16% with regional values
ranging from 5% in Asia Pacific to 25% in Europe.
Importantly, HF was identified by patient-reported
medical history at baseline (ie, including past and present
HF) and did not require documentation of natriuretic
peptide level or left ventricular ejection fraction. Prior
studies in the HF literature have highlighted marked
regional variation in HF diagnosis, severity and clinical
outcomes.12,13 Information on baseline HF prevalence is
particularly relevant given the uncertainty of the effects
of incretin-based therapy in patients with HF. In the
recent large-scale T2DM outcomes trial with the DPP-4
inhibitor saxagliptin (SAVOR), there were observations of 
increased hospitalization for HF.14,15 Increased hospital-
ization for HF has not been observed consistently with 
other DPP-4 inhibitors indicating the lack of a class effect. 
Specific data assessing HF effects with GLP-1RAs have 
also varied from no effect with lixisenatide4 or semaglu-
tide6 to a nominal reduction in HF events with liraglutide.5 
Reduced HF events were demonstrated with the sodium-
glucose co-transporter 2 (SGLT2) inhibitor empagliflo-
zin.16,17 Therefore, the HF-related findings from 
EXSCEL will provide much needed data regarding DM 
management in HF patients and/or those at increased 
risk for HF.
Limitations
Baseline characteristics were presented by world 
region using country groupings similar to prior cardio-
vascular outcome studies; however, there may be 
significant patient and provider level variation even 
within the same region. Additionally, baseline character-
istics were presented by prior cardiovascular disease 
status at randomization, the classification of which was 
determined by site investigators using available data 
regarding patients' medical history. However, there is the 
potential for misclassification of cardiovascular risk given 
that source documentation was not required for this 
determination. Moreover, the trial was pragmatic in 
nature and baseline labs were documented from routine 
care and not specifically drawn for the study. Nonethe-
less, these data provide important insights regarding the 
patient population of the multinational EXSCEL trial.
Conclusions
EXSCEL is one of the largest GLP-1RA trials, evaluating 
the effect of once weekly exenatide on cardiovascular 
safety and efficacy. Nearly half of the patients were 
enrolled in Europe with significant contributions from 
North America, Latin America, and Asia Pacific. Unique 
characteristics include a substantial percentage of pa-
tients with no prior cardiovascular event, and a notable 
percentage who were taking a DPP-4 inhibitor at 
baseline. The pragmatic design will support the general-
izability of the data due to the lack of an upper age limit, 
no run-in period, the inclusion of primary and secondary 
cardiovascular prevention patients, as well as a wide 
range of background DM medications.
Supplementary data to this article can be found online 
at http://dx.doi.org/10.1016/j.ahj.2017.02.005.Disclosures
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